SAN DIEGO, May 20, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that Anna Richo has joined the company's Board of Directors following shareholder approval of the director slate at the company's May 16, 2024, annual meeting. Ms. Richo currently serves as Corporate Senior Vice President, Strategic Advisor to the General Counsel and CEO at Cargill, Inc. a global food production and agricultural company.
Ms. Richo brings more than 30 years of regulated-industry experience as an attorney and legal executive, with extensive experience in compliance and business ethics, intellectual property, and corporate litigation. She formerly served as Corporate Senior Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary at Cargill, where she oversaw the company's corporate governance, global ethics and compliance, global security, global government relations, law, and shareholder relations functions.
Prior to joining Cargill, Ms. Richo was Executive Vice President and General Counsel at UCB, a biopharmaceutical company based in Belgium. She also served as Senior Vice President and Chief Compliance Officer at Amgen, a global biotechnology company, and as Chief Litigation Counsel, Associate General Counsel, and Vice President of Law at Baxter Healthcare.
"I am thrilled to welcome Anna to our Board of Directors," said Jacob Thaysen, CEO of Illumina. "In today's evolving business and regulatory environment, her extensive global legal, compliance, and regulatory experience, including at biotechnology, biopharmaceutical, and medtech companies, will enhance our evaluation and understanding of the risks and opportunities associated with Illumina's expanding worldwide operations."
Ms. Richo also serves as a member of Exelon's Board of Directors, as a member of the Cargill Foundation Board of Directors, on the Board of Trustees for DePaul University, and on the Children's Minnesota Governance Board.
Ms. Richo holds a B.S. in Industrial and Labor Relations from Cornell University and a J.D. from DePaul University College of Law.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X(Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Investors:
Salli Schwartz
858-291-6421
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Bonny Fowler
740-641-5579
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$140.14 |
Daily Change: | 3.15 2.30 |
Daily Volume: | 1,919,548 |
Market Cap: | US$22.320B |
November 19, 2024 November 04, 2024 October 31, 2024 October 09, 2024 August 27, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB